Recon: Biden administration exercises authority to seize certain drug patents; Abbvie buys neuro developer Cerevel for $8.7B

• Targeting costly meds, Biden admin asserts authority to seize certain drug patents (POLITICO)
• Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfalls (Fierce Pharma)
• Eli Lilly’s latest $1.4 billion deal might come unglued (STAT)
• FDA endorses Novartis’ ‘pipeline in a pill,’ granting first nod for potential blockbuster Fabhalta (Fierce Pharma)
• AbbVie purchases neuroscience developer Cerevel for $8.7 billion (STAT)
• New England Journal of Medicine reckons with its racist past and complicity in slavery (STAT)
• ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices (STAT)
• Biden Rx Pricing Plan Includes Antitrust Scrutiny, Patent ‘March-In’ Actions (Pink Sheet)

• What is the EU AI Act and when will regulation come into effect? (Reuters)
• EU’s Talks on AI Rules Stall After Nearly 24 Hours of Debate (Bloomberg)
• Denmark Introduces Early Dialogue With Procurement Agency For Expensive Medicines (Pink Sheet)
• HIV vaccine trial in Africa halted after disappointing data (Reuters)
• EU Lists Its First Reference Laboratories For High-Risk IVDs Falling Into Class D (MedTech Insight)
• EU Critical Medicines List To Be Ready ‘Within Days’ (Pink Sheet)
• What To Expect From India’s Proposed National Pharmaceutical Policy (Pink Sheet)
• Japan Law Revisions Allow Medical Cannabis But Tighten Other Restrictions (Pink Sheet)

• Pfizer plans to depart BIO (STAT)
• New gene therapies confront many sickle cell patients with an impossible choice: a cure or fertility (STAT)
• Merck's lung cancer drug combo fails trial in setback for new therapy class (Reuters)
• Sanfilippo Syndrome Patients, Drug Developers At Odds With US FDA Guidance (Pink Sheet)
• Sanofi to boost drug development spend by 700 mln euros in 2024 (Reuters)
• Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it? (STAT)

• US FDA clears Becton's less-invasive blood collection device (Reuters)
• 5 takeaways from J&J’s investor day (MedTech Dive)
• US hospitals forecast 9% capex growth to support elective procedure backlog: survey (MedTech Dive)
• Mosie Baby First To Win FDA Clearance For At-Home DYI Artificial Insemination Kit (MedTech Insight)
• MDR Changes Aren’t A ‘Catalyst’ For Medtech Investments In Ireland (MedTech Insight)
• “We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business (MedTech Insight)
• eSTAR Now Open For PMA Submissions (MedTech Insight)
• FDA Evaluating Safety Of Plastic Syringes From China, May Prevent Their Import To The US (MedTech Insight)

• Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case (Fierce Pharma)
• HP&M Files Comments Opposing FDA’s Proposed LDT Rule (FDA Law Blog)
• As Biopharma Seeks Broader IRA Orphan Exclusion, Study Urges Boosting Savings By Eliminating It (Pink Sheet)
• The History Behind The Drug-Device Combos Targeted By FTC (Pink Sheet)